Conjunctival Goblet Cell Secretion Stimulated by Leukotrienes Is Reduced by Resolvins D1 and E1 To Promote Resolution of Inflammation

The conjunctiva is a mucous membrane that covers the sclera and lines the inside of the eyelids. Throughout the conjunctiva are goblet cells that secrete mucins to protect the eye. Chronic inflammatory diseases such as allergic conjunctivitis and early dry eye lead to increased goblet cell mucin secretion into tears and ocular surface disease. The purpose of this study was to determine the actions of the inflammatory mediators, the leukotrienes and the proresolution resolvins, on secretion from cultured rat and human conjunctival goblet cells. We found that both cysteinyl leukotriene (CysLT) receptors, CysLT1 and CysLT2, were present in rat conjunctiva and in rat and human cultured conjunctival goblet cells. All leukotrienes LTB4, LTC4, LTD4, and LTE4, as well as PGD2, stimulated goblet cell secretion in rat goblet cells. LTD4 and LTE4 increased the intracellular Ca2+ concentration ([Ca2+]i), and LTD4 activated ERK1/2. The CysLT1 receptor antagonist MK571 significantly decreased LTD4-stimulated rat goblet cell secretion and the increase in [Ca2+]i. Resolvins D1 (RvD1) and E1 (RvE1) completely reduced LTD4-stimulated goblet cell secretion in cultured rat goblet cells. LTD4-induced secretion from human goblet cells was blocked by RvD1. RvD1 and RvE1 prevented LTD4- and LTE4-stimulated increases in [Ca2+]i, as well as LTD4 activation of ERK1/2. We conclude that cysteinyl leukotrienes stimulate conjunctival goblet cell mucous secretion with LTD4 using the CysLT1 receptor. Stimulated secretion is terminated by preventing the increase in [Ca2+]i and activation of ERK1/2 by RvD1 and RvE1.

[1]  C. Serhan,et al.  Resolvin D1 binds human phagocytes with evidence for proresolving receptors , 2010, Proceedings of the National Academy of Sciences.

[2]  B. Jessen,et al.  Corneal Neovascularization and Ocular Irritancy Responses in Dogs Following Topical Ocular Administration of an EP4-Prostaglandin E2 Agonist , 2009, Toxicologic pathology.

[3]  C. Serhan,et al.  Resolvin E1 Receptor Activation Signals Phosphorylation and Phagocytosis* , 2009, The Journal of Biological Chemistry.

[4]  S. Paruchuri,et al.  Leukotriene E4–induced pulmonary inflammation is mediated by the P2Y12 receptor , 2009, The Journal of experimental medicine.

[5]  R. Dana,et al.  Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. , 2009, Investigative ophthalmology & visual science.

[6]  Jeffrey A. Bair,et al.  Stimulatory role of PKCalpha in extracellular regulated kinase 1/2 pathway in conjunctival goblet cell proliferation. , 2009, Investigative ophthalmology & visual science.

[7]  William Farley,et al.  Tear cytokine profiles in dysfunctional tear syndrome. , 2009, American journal of ophthalmology.

[8]  Guoxing Wang,et al.  Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. , 2009, Differentiation; research in biological diversity.

[9]  M. Toner,et al.  Rapid Appearance of Resolvin Precursors in Inflammatory Exudates: Novel Mechanisms in Resolution1 , 2008, The Journal of Immunology.

[10]  C. Serhan,et al.  An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption , 2008, British journal of pharmacology.

[11]  C. Serhan Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators. , 2008, Prostaglandins, leukotrienes, and essential fatty acids.

[12]  B. Levy,et al.  Resolvin E1 regulates interleukin 23, interferon-γ and lipoxin A4 to promote the resolution of allergic airway inflammation , 2008, Nature Immunology.

[13]  J. Gu,et al.  ERK/p44p42 mitogen-activated protein kinase mediates EGF-stimulated proliferation of conjunctival goblet cells in culture. , 2008, Investigative ophthalmology & visual science.

[14]  Charles N. Serhan,et al.  Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators , 2008, Nature Reviews Immunology.

[15]  T. Ishizuka,et al.  Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. , 2008, Biochemical and biophysical research communications.

[16]  M. Stern,et al.  Ocular anti‐allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[17]  Lois E. H. Smith,et al.  Increased dietary intake of ω-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis , 2007, Nature Medicine.

[18]  Carolyn G. Begley,et al.  The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[19]  J. Gu,et al.  Role of neurotrophins and neurotrophin receptors in rat conjunctival goblet cell secretion and proliferation. , 2007, Investigative ophthalmology & visual science.

[20]  Christophe Baudouin,et al.  The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[21]  J. Uddin,et al.  Resolvin D1 and Its Aspirin-triggered 17R Epimer , 2007, Journal of Biological Chemistry.

[22]  C. Serhan Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. , 2007, Annual review of immunology.

[23]  J. Duffield,et al.  Resolvin D Series and Protectin D1 Mitigate Acute Kidney Injury1 , 2006, The Journal of Immunology.

[24]  B. Schultz,et al.  Pharmacology of ocular allergy , 2006, Current opinion in allergy and clinical immunology.

[25]  B. Levy,et al.  RvE1 protects from local inflammation and osteoclastmediated bone destruction in periodontitis , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  Makoto Arita,et al.  Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Sher,et al.  Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1 , 2005, The Journal of experimental medicine.

[28]  Santa Jeremy Ono,et al.  Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. , 2005, The Journal of allergy and clinical immunology.

[29]  V. Capra Molecular and functional aspects of human cysteinyl leukotriene receptors. , 2004, Pharmacological research.

[30]  Heung-Man Lee,et al.  Up-regulation of MUC5AC and MUC5B mucin genes in chronic rhinosinusitis. , 2004, Archives of otolaryngology--head & neck surgery.

[31]  M. Parmentier,et al.  The C-terminal Nonapeptide of Mature Chemerin Activates the Chemerin Receptor with Low Nanomolar Potency* , 2004, Journal of Biological Chemistry.

[32]  D. Dartt Control of mucin production by ocular surface epithelial cells. , 2004, Experimental eye research.

[33]  R. Hodges,et al.  Isolation and characterization of cultured human conjunctival goblet cells. , 2003, Investigative ophthalmology & visual science.

[34]  D. Zoukhri,et al.  Activation of mitogen-activated protein kinase by cholinergic agonists and EGF in human compared with rat cultured conjunctival goblet cells. , 2003, Investigative ophthalmology & visual science.

[35]  G. Rasi,et al.  Montelukast, a leukotriene receptor antagonist, in vernal keratoconjunctivitis associated with asthma. , 2003, Archives of ophthalmology.

[36]  D. Zoukhri,et al.  Cholinergic agonists transactivate EGFR and stimulate MAPK to induce goblet cell secretion. , 2003, American journal of physiology. Cell physiology.

[37]  D. Rogers The airway goblet cell. , 2003, The international journal of biochemistry & cell biology.

[38]  G. Scadding,et al.  Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. , 2002, The New England journal of medicine.

[39]  C. Serhan,et al.  Resolvins , 2002, The Journal of experimental medicine.

[40]  N. Nieto,et al.  Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis. , 2002, The Journal of nutrition.

[41]  D. Zoukhri,et al.  Regulation of conjunctival goblet cell secretion by Ca(2+)and protein kinase C. , 2000, Experimental eye research.

[42]  C. Clish,et al.  Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2–Nonsteroidal Antiinflammatory Drugs and Transcellular Processing , 2000, The Journal of experimental medicine.

[43]  D. Dartt,et al.  Development of conjunctival goblet cells and their neuroreceptor subtype expression. , 2000, Investigative ophthalmology & visual science.

[44]  D. Zoukhri,et al.  Immunolocalization of muscarinic and VIP receptor subtypes and their role in stimulating goblet cell secretion. , 1999, Investigative ophthalmology & visual science.

[45]  C. D. Richardson,et al.  5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. , 1993, European journal of biochemistry.

[46]  C. Labat,et al.  A second cysteinyl leukotriene receptor in human lung. , 1992, The Journal of pharmacology and experimental therapeutics.

[47]  D. Woodward,et al.  Platelet-activating factor causes goblet cell depletion in the conjunctiva. , 1989, European journal of pharmacology.

[48]  S. Dahlén,et al.  Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. , 1987, Science.